Efficacy of Triprolidine in the Treatment of Temporary Sleep Disturbance. (22nd April 2021)

• Record Type: Journal Article
• Authors: Cravo, Ana Santos; Shephard, Adrian; Shea, Tim
• Is Part Of: Journal of clinical pharmacology. Volume 61:Number 9(2021)
• Page Start: 1156
• Page End: 1164
• Publication Date: 2021-04-22
• Subjects: antihistamines -- insomnia -- over‐the‐counter drugs -- temporary sleep disturbance -- triprolidine; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1861
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Triprolidine, a first‐generation antihistamine for allergic rhinitis, has a shorter half‐life and fewer persistent effects relative to other antihistamines and may be useful in the treatment of temporary sleep disturbance. Patients aged ≥18 years old were randomized 1:1:1 to receive either triprolidine 2.5 mg (n = 65), triprolidine 5 mg (n = 66), or placebo (n = 67) on 3 consecutive nights. Sleep disturbance index was monitored via wrist actimeter. Subjective measures were assessed via diary card. Triprolidine 2.5 mg had a significantly lower sleep disturbance index versus placebo on night 1 ( P = .02); however, when adjusted for outliers, sleep disturbance index did not significantly differ between either dose of triprolidine versus placebo on night 1. Adjusted sleep disturbance index was significantly lower with triprolidine 2.5 and 5 mg versus placebo on night 3 ( P = .0017 and P = .011, respectively) and for the mean of all 3 nights ( P = .01 and P = .015, respectively). Sleep latency was significantly improved for triprolidine 2.5 mg versus placebo on nights 2 and 3 and for the mean of all 3 nights and for triprolidine 5 mg versus placebo for the mean of all 3 nights. Subjective measures showed those on both doses of triprolidine felt more refreshed on awakening versus placebo for the mean of all 3 nights, with no increase in daytime sleepiness. The frequency of adverse events was similar across groups. The optimum dose of triprolidine for treatment of temporary sleep disturbance was 2.5 mg. There were improvements in both objective and subjective measures of sleep quality versus placebo, with no safety concerns raised.